FDA generic biologics document delayed
Executive Summary
Development of FDA background document on generic biologics is delayed while senior management addresses drug safety issues raised during the year. The goal of the document is to harmonize review practices of biologics used to treat different diseases; it was due out in 2004 (1"The Pink Sheet" Nov. 1, 2004, p. 16)...